MX-3253 (celgosivir) is a novel, oral antiviral agent under development for the treatment of chronic Hepatitis C Virus (HCV) infection. MIGENIX obtained Health Canada CTA approval to initiate a Phase IIa study in HCV patients in September 2004 and is currently enrolling patients.

MX-226 is a novel, topical antibiotic for the prevention of catheter-related  infections. A Phase III clinical trial of MX-226 was completed in July 2003. MX-226 is partnered with Cadence Pharmaceuticals, Inc. in North America and Europe. Cadence intends to obtain a Special Protocol Assessment (SPA) from the US FDA for a pivotal Phase III study of MX-226 which is forecast to be initiated in the first half of calendar 2005.

MX-594AN is a novel, topical antibiotic for the treatment of acne (Phase IIa completed Q4 calendar 2001 - Phase IIb completed Q4 calendar 2003). We are currently seeking a development & commercialization partner for MX-594AN.